Trifluoroacetic acid → Ethyl 4-(2-oxo-1,4-dihydropyrido[3,4-d]pyrimidin-3(2H)-yl)piperidine-1-carboxylate

HRID 501098

Reaktionsgleichung

Reaktionsgleichung von HRID 501098
FC(F)(F)C(O)=O.C([O:12][C:13]([NH:15][C:16]1[CH:17]=[N:18][CH:19]=[CH:20][C:21]=1[CH2:22][NH:23][CH:24]1[CH2:29][CH2:28][N:27]([C:30]([O:32][CH2:33][CH3:34])=[O:31])[CH2:26][CH2:25]1)=O)(C)(C)C.C(N1C=CN=C1)(N1C=CN=C1)=O>ClCCl>[O:12]=[C:13]1[NH:15][C:16]2[CH:17]=[N:18][CH:19]=[CH:20][C:21]=2[CH2:22][N:23]1[CH:24]1[CH2:29][CH2:28][N:27]([C:30]([O:32][CH2:33][CH3:34])=[O:31])[CH2:26][CH2:25]1

Komponenten

5

Versuchsvorschrift

Trifluoroacetic acid (1.43 g) was added to a solution of the material from Step A (0.47 g, 1.24 mmol) in dichloromethane (10 mL). After stirring overnight, the reaction was concentrated. This material was dissolved in acetonitrile (5 mL) and carbonyldiimidazole (0.62 g, 3.73 mmol) was added at room temperature. After 2 d, the acetonitrile was evaporated in vacuo, the residue partitioned between 1N NaOH and dichloromethane, and the organic phase dried over magnesium sulfate. The crude product was purified by chromatography (silica gel, 1 to 20% methanol in methylene chloride gradient elution), which gave the title compound (0.15 g). MS 305.2.

Aufarbeitung

  1. concentrationthe reaction was concentrated
  2. dissolutionThis material was dissolved in acetonitrile (5 mL)
  3. waitAfter 2 d
  4. customthe acetonitrile was evaporated in vacuo
  5. customthe residue partitioned between 1N NaOH and dichloromethane
  6. dry with materialthe organic phase dried over magnesium sulfate
  7. customThe crude product was purified by chromatography (silica gel, 1 to 20% methanol in methylene chloride gradient elution), which

Quellen und Nachweise

ORD-Eintrag
ord-8c615ccbe143489f8df25bacc08292e2
Quelldatensatz
uspto-grants-2010_08
Patentnummer
US07772224B2

Verknüpfte Notizen

Wird geladen…